Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database

To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer. Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical cancer research Ročník 25; číslo 6; s. 1970
Hlavní autori: Hwang, Ki-Tae, Kim, Jongjin, Jung, Jiwoong, Chang, Ji Hyun, Chai, Young Jun, Oh, So Won, Oh, Sohee, Kim, Young A, Park, Sung Bae, Hwang, Kyu Ri
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 15.03.2019
Predmet:
Adult
Aged
Breast - pathology
Breast - surgery
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Mastectomy
Middle Aged
Neoplasm Invasiveness - pathology
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
SEER Program - statistics & numerical data
Survival Rate
ISSN:1078-0432, 1557-3265, 1557-3265
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer. Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of hormone receptor (HRc) and HER2: HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), and HRc(-)/HER2(-). Proportions of HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), HRc(-)/HER2(-), and unknown subtype were 70.3%, 9.4%, 3.9%, 10.4%, and 6.0%, respectively. HRc(+)/HER2(-) showed the highest 5-year breast cancer-specific survival (BCSS) rate (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(-)/HER2(+) (89.3%), and HRc(-)/HER2(-) (83.1%). HRc(+)/HER2(-) and HRc(+)/HER2(+) showed higher 5-year overall survival (OS) rates (88.4% and 88.2%, respectively) than HRc(-)/HER2(+) and HRc(-)/HER2(-) (83.9% and 76.5%, respectively). HRc(-)/HER2(-) showed the worst BCSS irrespective of race, age, or stage. Although proportions of HRc(-)/HER2(-) in the subgroup with negative event regarding BCSS and OS were 10.4% and 10.2%, respectively, they were 34.2% and 22.7%, respectively, in the subgroup with positive event. Subtype was a significant factor in both univariable and multivariable analyses regarding both BCSS and OS (all < 0.001). Breast cancer subtype was a significant independent prognostic factor regarding both BCSS and OS in multivariable analyses. HRc(+) subtypes showed better prognosis compared with HRc(-) subtypes regarding both BCSS and OS. HRc(-)/HER2(+) showed better prognosis than HRc(-)/HER2(-) but worse prognosis than HRc(+) subtypes regarding both BCSS and OS. The triple-negative subtype showed the worst BCSS compared with the other subtypes irrespective of race, age, or stage.
AbstractList To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer. Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of hormone receptor (HRc) and HER2: HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), and HRc(-)/HER2(-). Proportions of HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), HRc(-)/HER2(-), and unknown subtype were 70.3%, 9.4%, 3.9%, 10.4%, and 6.0%, respectively. HRc(+)/HER2(-) showed the highest 5-year breast cancer-specific survival (BCSS) rate (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(-)/HER2(+) (89.3%), and HRc(-)/HER2(-) (83.1%). HRc(+)/HER2(-) and HRc(+)/HER2(+) showed higher 5-year overall survival (OS) rates (88.4% and 88.2%, respectively) than HRc(-)/HER2(+) and HRc(-)/HER2(-) (83.9% and 76.5%, respectively). HRc(-)/HER2(-) showed the worst BCSS irrespective of race, age, or stage. Although proportions of HRc(-)/HER2(-) in the subgroup with negative event regarding BCSS and OS were 10.4% and 10.2%, respectively, they were 34.2% and 22.7%, respectively, in the subgroup with positive event. Subtype was a significant factor in both univariable and multivariable analyses regarding both BCSS and OS (all < 0.001). Breast cancer subtype was a significant independent prognostic factor regarding both BCSS and OS in multivariable analyses. HRc(+) subtypes showed better prognosis compared with HRc(-) subtypes regarding both BCSS and OS. HRc(-)/HER2(+) showed better prognosis than HRc(-)/HER2(-) but worse prognosis than HRc(+) subtypes regarding both BCSS and OS. The triple-negative subtype showed the worst BCSS compared with the other subtypes irrespective of race, age, or stage.
To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer.Experimental Design: Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of hormone receptor (HRc) and HER2: HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), and HRc(-)/HER2(-).PURPOSETo determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer.Experimental Design: Data of 321,958 patients from Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Breast cancer subtypes were classified into four categories according to the status of hormone receptor (HRc) and HER2: HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), and HRc(-)/HER2(-).Proportions of HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), HRc(-)/HER2(-), and unknown subtype were 70.3%, 9.4%, 3.9%, 10.4%, and 6.0%, respectively. HRc(+)/HER2(-) showed the highest 5-year breast cancer-specific survival (BCSS) rate (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(-)/HER2(+) (89.3%), and HRc(-)/HER2(-) (83.1%). HRc(+)/HER2(-) and HRc(+)/HER2(+) showed higher 5-year overall survival (OS) rates (88.4% and 88.2%, respectively) than HRc(-)/HER2(+) and HRc(-)/HER2(-) (83.9% and 76.5%, respectively). HRc(-)/HER2(-) showed the worst BCSS irrespective of race, age, or stage. Although proportions of HRc(-)/HER2(-) in the subgroup with negative event regarding BCSS and OS were 10.4% and 10.2%, respectively, they were 34.2% and 22.7%, respectively, in the subgroup with positive event. Subtype was a significant factor in both univariable and multivariable analyses regarding both BCSS and OS (all P < 0.001).RESULTSProportions of HRc(+)/HER2(-), HRc(+)/HER2(+), HRc(-)/HER2(+), HRc(-)/HER2(-), and unknown subtype were 70.3%, 9.4%, 3.9%, 10.4%, and 6.0%, respectively. HRc(+)/HER2(-) showed the highest 5-year breast cancer-specific survival (BCSS) rate (95.5%), followed by HRc(+)/HER2(+) (94.1%), HRc(-)/HER2(+) (89.3%), and HRc(-)/HER2(-) (83.1%). HRc(+)/HER2(-) and HRc(+)/HER2(+) showed higher 5-year overall survival (OS) rates (88.4% and 88.2%, respectively) than HRc(-)/HER2(+) and HRc(-)/HER2(-) (83.9% and 76.5%, respectively). HRc(-)/HER2(-) showed the worst BCSS irrespective of race, age, or stage. Although proportions of HRc(-)/HER2(-) in the subgroup with negative event regarding BCSS and OS were 10.4% and 10.2%, respectively, they were 34.2% and 22.7%, respectively, in the subgroup with positive event. Subtype was a significant factor in both univariable and multivariable analyses regarding both BCSS and OS (all P < 0.001).Breast cancer subtype was a significant independent prognostic factor regarding both BCSS and OS in multivariable analyses. HRc(+) subtypes showed better prognosis compared with HRc(-) subtypes regarding both BCSS and OS. HRc(-)/HER2(+) showed better prognosis than HRc(-)/HER2(-) but worse prognosis than HRc(+) subtypes regarding both BCSS and OS. The triple-negative subtype showed the worst BCSS compared with the other subtypes irrespective of race, age, or stage.CONCLUSIONSBreast cancer subtype was a significant independent prognostic factor regarding both BCSS and OS in multivariable analyses. HRc(+) subtypes showed better prognosis compared with HRc(-) subtypes regarding both BCSS and OS. HRc(-)/HER2(+) showed better prognosis than HRc(-)/HER2(-) but worse prognosis than HRc(+) subtypes regarding both BCSS and OS. The triple-negative subtype showed the worst BCSS compared with the other subtypes irrespective of race, age, or stage.
Author Park, Sung Bae
Kim, Jongjin
Oh, Sohee
Chai, Young Jun
Hwang, Ki-Tae
Kim, Young A
Jung, Jiwoong
Chang, Ji Hyun
Hwang, Kyu Ri
Oh, So Won
Author_xml – sequence: 1
  givenname: Ki-Tae
  orcidid: 0000-0001-6597-3119
  surname: Hwang
  fullname: Hwang, Ki-Tae
  email: kiterius@snu.ac.kr
  organization: Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. kiterius@snu.ac.kr
– sequence: 2
  givenname: Jongjin
  surname: Kim
  fullname: Kim, Jongjin
  organization: Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 3
  givenname: Jiwoong
  surname: Jung
  fullname: Jung, Jiwoong
  organization: Department of Surgery, Seoul Medical Center, Seoul, Republic of Korea
– sequence: 4
  givenname: Ji Hyun
  surname: Chang
  fullname: Chang, Ji Hyun
  organization: Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 5
  givenname: Young Jun
  surname: Chai
  fullname: Chai, Young Jun
  organization: Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 6
  givenname: So Won
  orcidid: 0000-0002-3010-448X
  surname: Oh
  fullname: Oh, So Won
  organization: Department of Nuclear Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 7
  givenname: Sohee
  orcidid: 0000-0002-3010-448X
  surname: Oh
  fullname: Oh, Sohee
  organization: Department of Biostatistics, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 8
  givenname: Young A
  surname: Kim
  fullname: Kim, Young A
  organization: Department of Pathology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 9
  givenname: Sung Bae
  surname: Park
  fullname: Park, Sung Bae
  organization: Department of Neurosurgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
– sequence: 10
  givenname: Kyu Ri
  orcidid: 0000-0001-6845-1260
  surname: Hwang
  fullname: Hwang, Kyu Ri
  organization: Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30559169$$D View this record in MEDLINE/PubMed
BookMark eNpVkLFOwzAYhC0EAlp4BJBHloDt2I7DBqFApUqglooxspM_EJTYIXaK-gi8Na0oA9OddN_dcCO0b50FhM4ouaRUqCtKEhURHrPLLJtHVEUsUWwPHVMhkihmUuxv_B9zhEbefxBCOSX8EB3FRIiUyvQYfU_bThcBuwrf9qB9wJm2BfR4MZiw7sBjZ_Fz796s87XfYq-uBYu_6vCOnzrotWkAT-1K-3oF_zeu8Q1-dt3Q6FA7GxntocSLMJRrvPS1fcOLyWSO73TQ2-gEHVS68XC60zFa3k9essdo9vQwzW5mURGTNEQpqSqutUgEyBSEUlIynmoDokoMieOSKlmweHORkNRwVZiyhJgbyRNhCqrZGF387na9-xzAh7ytfQFNoy24wedsU2Vc0URs0PMdOpgWyrzr61b36_zvPvYDnvF0wg
CitedBy_id crossref_primary_10_1096_fj_202500221R
crossref_primary_10_1016_j_inffus_2025_103326
crossref_primary_10_1007_s11523_020_00730_0
crossref_primary_10_1007_s10549_025_07814_3
crossref_primary_10_1186_s12967_025_06153_7
crossref_primary_10_1007_s11033_024_09380_1
crossref_primary_10_4103_jcrt_jcrt_56_23
crossref_primary_10_1210_jendso_bvac186
crossref_primary_10_1007_s10549_020_05976_w
crossref_primary_10_1007_s00335_025_10137_9
crossref_primary_10_1016_j_biopha_2019_108990
crossref_primary_10_1016_j_cpet_2023_12_002
crossref_primary_10_1016_j_breast_2022_03_002
crossref_primary_10_3892_ijo_2019_4885
crossref_primary_10_1186_s12905_023_02637_0
crossref_primary_10_1097_MD_0000000000030922
crossref_primary_10_1186_s13046_025_03441_4
crossref_primary_10_1097_MS9_0000000000001030
crossref_primary_10_5858_arpa_2019_0904_SA
crossref_primary_10_1053_j_semdp_2022_06_015
crossref_primary_10_3390_cancers14112692
crossref_primary_10_1097_GCO_0000000000000671
crossref_primary_10_1016_j_jgo_2024_101805
crossref_primary_10_1016_j_critrevonc_2022_103880
crossref_primary_10_1016_j_jconrel_2022_04_045
crossref_primary_10_3390_jpm13071062
crossref_primary_10_1097_PPO_0000000000000498
crossref_primary_10_1016_j_hpr_2021_300574
crossref_primary_10_1093_oncolo_oyae095
crossref_primary_10_1186_s13020_022_00597_5
crossref_primary_10_3390_cancers13194858
crossref_primary_10_3389_fonc_2023_1231302
crossref_primary_10_1007_s10549_019_05456_w
crossref_primary_10_1245_s10434_021_10129_4
crossref_primary_10_1186_s13578_023_01153_w
crossref_primary_10_1016_j_amjsurg_2023_03_003
crossref_primary_10_36303_SAJS_01118
crossref_primary_10_1016_j_annonc_2023_09_3104
crossref_primary_10_1016_j_annonc_2023_09_3103
crossref_primary_10_3389_fonc_2022_913929
crossref_primary_10_1016_j_cpet_2023_04_008
crossref_primary_10_1093_jncimonographs_lgad011
crossref_primary_10_3389_fonc_2021_746058
crossref_primary_10_1016_j_biopha_2025_118359
crossref_primary_10_1016_j_biopha_2022_113635
crossref_primary_10_1148_radiol_240315
crossref_primary_10_1038_s41419_020_03188_0
crossref_primary_10_1186_s12885_025_13681_4
crossref_primary_10_1016_j_bulcan_2020_11_007
crossref_primary_10_1016_j_advms_2022_09_001
crossref_primary_10_1016_j_gene_2022_146245
crossref_primary_10_1002_onco_13938
crossref_primary_10_1001_jamanetworkopen_2023_30791
crossref_primary_10_1016_j_clbc_2023_10_006
crossref_primary_10_1002_onco_13813
crossref_primary_10_3233_BD_201063
crossref_primary_10_2478_prolas_2023_0004
crossref_primary_10_3390_cancers14092215
crossref_primary_10_3897_folmed_66_e113837
crossref_primary_10_1097_MS9_0000000000002293
crossref_primary_10_1155_2019_8186091
crossref_primary_10_3390_nu14010079
crossref_primary_10_1097_PAP_0000000000000416
crossref_primary_10_31083_j_fbl2902081
crossref_primary_10_3390_ijms20225740
crossref_primary_10_3390_biomedicines11112906
crossref_primary_10_1097_CEJ_0000000000000869
crossref_primary_10_1158_1078_0432_CCR_20_4102
crossref_primary_10_7759_cureus_84418
crossref_primary_10_1158_1078_0432_CCR_19_2612
crossref_primary_10_1186_s13058_024_01843_4
crossref_primary_10_1016_j_molimm_2025_02_014
crossref_primary_10_1136_jitc_2023_007126
crossref_primary_10_1186_s13058_025_02056_z
crossref_primary_10_1002_cncr_32207
crossref_primary_10_1371_journal_pone_0274691
crossref_primary_10_1016_j_csbj_2023_05_002
crossref_primary_10_1111_1759_7714_14715
crossref_primary_10_1053_j_semnuclmed_2022_03_002
crossref_primary_10_3390_ijms231810319
crossref_primary_10_1371_journal_pone_0312036
crossref_primary_10_1186_s13058_021_01492_x
crossref_primary_10_2147_OTT_S400563
crossref_primary_10_36469_001c_137277
crossref_primary_10_1111_apm_13026
crossref_primary_10_2217_fon_2022_0310
crossref_primary_10_1111_his_14767
crossref_primary_10_3390_ijms222413571
crossref_primary_10_2147_CMAR_S299066
crossref_primary_10_1016_j_canlet_2021_12_009
crossref_primary_10_1371_journal_pone_0280474
crossref_primary_10_1007_s00066_024_02202_0
crossref_primary_10_1016_j_jep_2023_117322
crossref_primary_10_1007_s00432_022_04486_0
crossref_primary_10_3390_cancers14143305
crossref_primary_10_1038_s41416_021_01415_9
crossref_primary_10_1097_PPO_0000000000000715
crossref_primary_10_1038_s41571_024_00939_2
crossref_primary_10_36469_jheor_2025_137277
crossref_primary_10_1038_s41523_025_00799_8
crossref_primary_10_1186_s13058_021_01431_w
crossref_primary_10_1016_j_phrs_2020_104683
crossref_primary_10_1159_000546274
crossref_primary_10_1016_j_colsurfb_2025_114963
ContentType Journal Article
Copyright 2018 American Association for Cancer Research.
Copyright_xml – notice: 2018 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1078-0432.CCR-18-2782
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
ExternalDocumentID 30559169
Genre Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
NPM
OK1
P0W
P2P
QTD
RCR
RHF
RHI
RNS
SJN
TR2
W2D
W8F
WOQ
YKV
7X8
AAFWJ
AAJMC
ID FETCH-LOGICAL-c309t-90ff4aa575e69e58866249abe5f7b033d186c23158561b48cbdde34b6475bc1a2
IEDL.DBID 7X8
ISICitedReferencesCount 123
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000461476000029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1078-0432
1557-3265
IngestDate Fri Sep 05 12:54:12 EDT 2025
Wed Feb 19 02:30:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License 2018 American Association for Cancer Research.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c309t-90ff4aa575e69e58866249abe5f7b033d186c23158561b48cbdde34b6475bc1a2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3010-448X
0000-0001-6845-1260
0000-0001-6597-3119
PMID 30559169
PQID 2158248175
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2158248175
pubmed_primary_30559169
PublicationCentury 2000
PublicationDate 2019-03-15
PublicationDateYYYYMMDD 2019-03-15
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2019
SSID ssj0014104
Score 2.598429
Snippet To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer. Data of 321,958 patients from Surveillance,...
To determine the prognostic roles of breast cancer subtypes in females with operable invasive breast cancer.Experimental Design: Data of 321,958 patients from...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 1970
SubjectTerms Adult
Aged
Breast - pathology
Breast - surgery
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Mastectomy
Middle Aged
Neoplasm Invasiveness - pathology
Prognosis
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
SEER Program - statistics & numerical data
Survival Rate
Title Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
URI https://www.ncbi.nlm.nih.gov/pubmed/30559169
https://www.proquest.com/docview/2158248175
Volume 25
WOSCitedRecordID wos000461476000029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JT-swELbYhLiwP3Y0SFwNTeLYMRcEpQgOlIr3kHqrbMeWekn6moLET-BfM5MGEAckJC45ZLEiezzzebaPsWPrvNCxD9wplXChg-WZzT1vaaOdUcrL3NRkE6rbzfp93WscblWTVvmuE2tFnZeOfOSnaJqyWGRo7c5H_zmxRlF0taHQmGXzCUIZkmrV_4wiiKimD0STiRsplmlTwYMjobKgzrIiiU_a7QceobQo6sX3Hcqsrc31ym__c5UtNzgTLqaCscZmfLHOFu-aSPoGe72tyyOhDHBJeekTaNP6jwE1CbllKygL6I1LysMbVvRazXUJ5LeF-5EfU8kV3BbPhvLfv45xBhfQ-yAG42Qoc6CExReoMxTgb6fzAFdmYujRJnu87vxr3_CGloG7pKUnXLdCEMYgzvNS-zTLpMQznLE-Dcq2kiSPMukQNuJBREZWZM6iCk2ElUKl1kUm_sPmirLw2wzwpjM-D5FNgnAytT7WweP5XsSxzn20w47eJ3mAYk-xDFP48qkafE7zDtuartRgNO3PMaAmZoh69e4Pvt5jSwiBNGWVRek-mw-46f0BW3DPk2E1PqzlCa_d3t0bNxrV2g
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Breast+Cancer+Subtypes+on+Prognosis+of+Women+with+Operable+Invasive+Breast+Cancer%3A+A+Population-based+Study+Using+SEER+Database&rft.jtitle=Clinical+cancer+research&rft.au=Hwang%2C+Ki-Tae&rft.au=Kim%2C+Jongjin&rft.au=Jung%2C+Jiwoong&rft.au=Chang%2C+Ji+Hyun&rft.date=2019-03-15&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=25&rft.issue=6&rft.spage=1970&rft_id=info:doi/10.1158%2F1078-0432.CCR-18-2782&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon